Antibiotics profile map of clinical A. baumannii strains isolated from health institutions in Turkey: a database search study and analysis of publications from 2011 to 2022

Abed, Ahmed Badri; Korcan, Safiye Elif; Güngör, Serdar

doi:10.1186/s42269-023-00982-6

Bulletin of the National Research Centre

Table 2 Antibiotic Susceptibility profile Shown by A. baumannii clinical strains

From: Antibiotics profile map of clinical A. baumannii strains isolated from health institutions in Turkey: a database search study and analysis of publications from 2011 to 2022

N0	Antibiotics profile %
N0	R/S	AMC	AMP	AMS	ATM	AMK	CFPM	CTX	CS	CAZ	CRO	CIP	GEN	IPM	LVX
1.	R					68.1			63.9,	100		100		91. 7
2.	S								35
3.	S	0	0	60		13.3			73.3	13.3	0	46.7	20	53.3
4.	R			100		32	92	97	57	94	97	81	93	86
5.	R			53.3		40			36.6	86.6				20	60
6.	R					100	100							100
7.	R		100	100	100	100	100		0	100	100		100	100
8.	R			79.35		70.01		3.55		80.78		87.54	34.16	80.07	69.75
9.	R			100		100	100			100	100		100	100	100
10.	R								100	100		100	100	100
11.	R					64	95	96	89	94		92	90	71
12.	R					64			79			76	67	92	73
13.	R			100		100	100		100			100		100
14.	R					59	95		92			92	54	91	94
15.	R			82		86				95			89	57
16.	R			100		100				100	100	100	90	100
17.	R	96.8				71.7			73.5			86.8	74.7	72.1
18.	S2007					38							11	50
	08					26							10	23
	09					40							11	22
	10					48							22	20
19.	R	70.3	100			73						81.1	75.7	70.2
20.	R					53	86			93		86	86	86
21.	R					60
22.	R					73							65
23.	R					75.3	94.8	100	73.6	100	100		77.1	74.5
24.	R			97		63	97		87	97		94	48	95	89
25.	R											95
26.	R			76.8		67.1	82.9	84.1		86.6	85.4	84.1	76.8	73.2
27.	R			72.5		78.9	97.2			76.2		98.2	19.3	91.9
28.	R			96.8		44	95.3		94.2	96.1		95.7	84	93
29.	R					81	89	78		89		89	78
30.	R					79	78	85	77	84		85	85	91
31.	S					8.2	0		11.2	1.1		0	6.1	0
32.	R2008			95.7		88	97.6	98	45.7	100		98	96	54
	09			97.9		84.6	100	100	88.4	97.8		100	76.5	92.3
	10			90.6		81.8	100	98	78	97.9		96.2	66	94.4
	11			93.5		84.2	96.8	97.8	90.3	98.9		97.8	87.2	98.9
33.	S			0		14.8	0		1.85,	0		0	16.6	0
34.	R			87.5		65	89.5		89	94.5		97	82.5	91.5	95.5
35.	R			91.4		67.5	91.1			93.4		93.2	68.6	91.3	90.9
36.	S					13.7			20.7
37.	S			11.1		31.9	17.8	4.4	22.2	13.3		17	25.9	20	17.8
38.	R					59.375							53.125	56.25
39.	S					39.39	3.03		6.06	3.03			24.24	9.09
40.	R					35.2	93.7		79	96.8		97.3	77.2	89.1	95.2
41.	S			0		16.25	0	0		0	0	0		0
42.	R			91.7		79.3	94.7	98.9	69.5	94.9		91.7	82.1	91.1	89.5
43.	R					56						100
44.	R								100					100
45.	R						100			100		100
46.	R					46
47.	R	15.2	61.8	11.9		71.1	67.8		21	89.4	23.9	82.9	59.5	87.5	81.1
48.	R					62	100			100		99	62	100	90
49.	R			69.6		55.7			93.6	88.6		96.2	83.6	94.9	86
50.	R			13.1		65.6	32.8	92.7		78.7		77	72.1	73.8	74.6
51.	S
52.	R			100		100	100			100		100	100	100	100
53.	S			3.9		37				5.7		6.6	31	16
54.	S
55.	S					30	4			1		5	15,7	5,7
56.	R					50						90.47
57.	R
58.	R			94.07		94.81	97.03			98.51		98.51	86.62	98.51	97.77
59.	R			94		82			100			94	86	96
60.	R 2014				62.9								69.7
	16				63								74
61.	R						100	100		100	100	100		100	100
62.	R
63.	R			98.3		92	98.3		98.3	98.3		97.7	92	98	97.7
64.	R		99.5	98.6	99.8	89	99		96.2	98.9	100	98.8	95.8	97.1	97.5
65.	R			100		94.2	100				100	100	100	94.2
66.	R			99.4		91.8				99.4		100		99.4
67.	R					53				80.5		81	60.5
68.	R			62.8		59,3	74.6			71.2	72.8	73.7	63.5	73.7
69.	R			100		72.92	100			100		100	93.7	100	96.9
70.	R			74		40	93		69	95		100	47	95	82
71.	R					79				98		97	86	96
72.	R			86.1		90.7	97.5			96.7	96.5	95.6	89	94.9	93
73.	R			100		81			91	98.5		100	88
74.	R			100		53.5				100		97.7	60.5	100	93
75.	R			94.5		55.7	95.6			95.3		94.3	66.9	95.3	95.5
76.	R			100		52.9				100		100	55.7	100	100
77.	R					46.6				81.6		80.5	50.4
78.	R			72.7		68.2	72.7			75		72.7	70.5	72.7
79.	R					100						100	100	100
80.	S					26.5				2.9		2.9	26.5	2.9	2.9
81.	S						4.3							39.1	39.1
82.	R					100						100	100	100	100
83.						53						92	74	88
84.	R					12.5							25
85.	R									97.3			62.16	97.3	100.0
86.	R	100		95.7	100	97.8	100			100	100	95.7	95.7	97.8	91.3
87.	R					77.6	95.1			94.2		93.4	78.9	92.8	91
88.	R					93.3						96.6	92.9	96.7
89.	R2007				100		61.5	100		92.3		92.3		61.5	100
	08				91.7		80	100	0	91.4		91.4		74.3	90.3
	09						100	100	9.1	96.3		96.3		81.5	95.8
	10						100	100	16.7	100		100		100	71.4
90.	R					39.2				98.6		98.6	93.2	98.6
91.	R 2019–20			87.5		87.5				95		95	87.5	85
				100		98.5				100		100	82.3	100
	R 2020–21			66.6		83.3				83.3		83.3	83.3	83.3
				100		95				100		100	90.7	100

N0	Antibiotics profile %													References
N0	R/S	MEM	NET	PIP	TZP	SUL	TET	TOB	SXT	TCC	TGC	CST	Group/less use	References
1.	R		54.2		100						0			Tasbakan et al. (2011)
2.	S		61										Quinolones 11% carbapenems 8%	Turkoglu et al. (2011)
3.	S	46.7		0	6.7		0	66.7	6.7			100	CEF 0	Ozdemir et al. (2011)
4.	R	86			94				95		0	0		Uzun et al. (2012)
5.	R	20			80						0	0		Bayramoglu et al. (2012)
6.	R	100											TIC 100%	Aye et al. (2012)
7.	R	100	0	100	0									Hosoglu et al. (2012)
8.	R	78.29		90.03			70.46	40.56	81.13				CFM 81.13%	Çıçek et al. (2013)
9.	R	100	0	100					100		0	0		Cicek et al. (2013)
10.	R	100		100	100			100	100					Sarı et al. (2013)
11.	R	72			96		55					0		Bayram et al. (2015)
12.	R	92			84						0	0		Dede et al. (2013)
13.	R	100											PB 0% RIF 35% TIC 100%	Cetin et al. (2013)
14.	R	91			97						11			Gozutok et al. (2013)
15.	R	75	6	99			78	58	83			0	OFL 98%	Metan et al. (2013 Jun)
16.	R				100				95%					Ertugrul et al. (2013)
17.	R	73										0		Çi̇ftc et al. (2013
18.	S2007	55												Deveci et al. (2013)
	08	29
	09	25
	10	12
19.	R				81.1				64.9				CXM 97.3% cephalosporins 97.3% FOS 48.6%	Demir and Buyukguclu (2013)
20.	R	77			90						0	0		Bayram et al. (2013)
21.	R	86.6	26.6			26.6					6.6	0		Altun et al. (2014)
22.	R		36									0	100% resisters to all b-lactams,. 33% resistant to all aminoglycosides	Zeka et al. (2014)
23.	R	76.3						36.5						Aşik et al. (2014)
24.	R	94	89	97	97		70		69		92	0		Cicek et al. (2014)
25.	R	100						55				14		Bozkurt-Guzel et al. (2014)
26.	R			84.1	81.7			37.8	50.0					Gultekin et al. (2014)
27.	R	93.5	13.7		97.2			21.1	36.7		0	0		Ertürk et al. (2014)
28.	R	92.7			96		87.8		91.9		37.7	0		Sargin Altunok and Koc (2014)
29.	R				78		94		89		0	0		Cakirlar and Gonullu (2014)
30.	R	94	55		96			84	91		25	0		Kalin et al. (2014)
31.	S	0			0						55.1	100		Ece et al. (2014)
32.	R2008	73.5	41.7		91.7			54.2	91.7	97.9				Güven et al. (2014)
	09	98	52.1		100			54	85.4	100	12.5
	10	94.4	57.6		98.1			46.3	73.6	97.1	34.8
	11	98.9	53		98.9			68.1	72	98.5	81.3	2.9	DOR 100%
33.	S	0	14.8	0	0		80.5		22.2		59.2	100		Karagöz et al. (2014)
34.	R	92			96				67.5			6		Keskin et al. (2014)
35.	R	91.6			93.2						6.9	1.4		Doğan et al. (2014)
36.	S		41.3								27.6	99.71		Metan et al. (2014)
37.	S	17.7			17.8									Çolakoğlu et al. (2014)
38.	R	56.25												Atasoy et al. (2015)
39.	S	6.06			3.03						81.81	100		Ece et al. 2015
40.	R	90.3	19.5						68.9		41.3	5.5		Guckan et al. (2017)
41.	S	0	27.5		0			0	12.5		22.5	100		Özcan et al. (2015)
42.	R	89.8	97.2	97.4	92.8		97.7	25.4	81.2		5.1	0.8	NIT 99.1%	Di̇rekel et al. (2015)
43.	R	100				8					23	0		Temocin et al. (2015)
44.	R										1	0		Ak et al. (2016)
45.	R		57	100							2	0		Altun et al. (2016)
46.	R	83.3									5.7	0		Nemli and Demirdal (2016)
47.	R	78.6		69.2	48.6		66.3	22.9	77.5		2.7	0.6		Beriş et al. (2016)
48.	R	100		100	99		72		73			0		Gür Vural and Durupinar (2016)
49.	R	94.9	27.8		97.5		77.2		91.1		3.8	0		Direkel et al. (2016)
50.	R	73.8			75.4		76.4		72.1			5.1		Ruh et al. (2016)
51.	S					0			96		36	100	carbapenem.0%	Çetinkol et al. (2016)
52.	R	100			100		100		100			0		Guven Gokmen et al. (2016)
53.	S	13.1			7.4				11.7		93.9	96.5		Şafak et al. (2016)
54.	S	0				0					11.11	100		Yavaş et al. (2016)
55.	S	5,7			5							100		Barış et al. (2017)
56.	R	58.33									0	0	MOXI 22.62% RIF 47.62%	Büyük et al. (2017)
57.	R										66.7	0	Carbapenem 100%	Alp et al. (2017)
58.	R	98.51			97.77						10.37	0		Uzunoglu and Direkel (2017)
59.	R	96			92						0	100		Ceyhan-Guüvensen et al. (2017)
60.	R 2014											0		Karadag Gecgel and Demir (2017)
	16											6.8
61.	R	100			100			0				0	DOX 100% MIN 100%	Atik et al. (2018)
62.	R											2.1	Carbapenems 91.8 Fluoroquinolones 89% Third generation Cephalosporins 93.8% Aminoglycosides 70.9%	Aydın et al. (2018)
63.	R	98			98.6		93.7		80.6		26.6	0.3		Durdu et al. (2018)
64.	R	97.7	94.3	99.5	98.1		86.4		76.8	99.3	49.3	2.9	FO 100% ETP 99,6%	Şahin et al. (2019)
65.	R	94.2			94.2						0	0		Asgin et al. (2019)
66.	R										1.7	1.2		Boral et al. (2019)
67.	R	81.5			82						30	28		Çağlan et al. (2019)
68.	R	72.8			74.6				61.9					Gür and Hazırolan (2019)
69.	R	100			100						45.8	0		Say Coskun et al. (2019)
70.	R	95	21	100	100		83		53		2	0		Atik et al. (2019)
71.	R	96			99							0,5		Uğur and Genç (2019)
72.	R	95.2	92		97.6				73.9	97.5	11	2.5		Arabaci and Karabulut (2020)
73.	R		36	89	93			78	96					Gozalan et al. (2020)
74.	R	100			100				73.3		9.3	0		Kostakoğlu et al. (2020)
75.	R	96.1	43.3	99.6	98.9			47.5	68.9		21.7	3		Şimşek and Demir (2020)
76.	R	100			100				100		11.4	0		Ozyurt et al. (2020)
77.	R	81.7			83.5				59		22	1.8		Ozekinci et al. (2020)
78.	R	72.7	72.7		72.7				81.8			13.6		Özkul and Hazırolan (2020)
79.	R	100						100	79.3			100		Yilmaz et al. (2020)
80.	S	2.9	20.6		2.9				17.7		41.2	82.4	DOX 8.8% MIN 23.5%	Gorgun et al. (2020)
81.	S	7.1			4.3	26.1						100	CFP 34.8%	Tasdogan (2020)
82.	R	100						100	100					Doğan and Gezer (2021)
83.		88						67	63		10			Albayrak et al. (2021)
84.	R								100			12.5	Carbapenems 75% Cephalosporins,Quinolones100%	Ayhan et al. (2021)
85.	R	97.3	62.16	100	97.3			67.57	83.78		0	0		Saral et al. (2021)
86.	R	97.8			100				58.7		73.9	2.2	CEF 100% ETP 97.8% NIT 97.8%	Konca et al. (2021)
87.	R	93.1	75.7	96.2	91.6			60.8	75.6		18.6	12.8		Uskudar Guclu et al. (2021)
88.	R	96.9							85.7		5.9	9.1		Çil et al. (2022)
89.	R2007	58.3		100					92.3				CPL 100%	Güler et al. (2022)
	08	71.4		100	95.5				85.7			0	CPL 100%
	09	81.5		100	100				96.3
	10	100		100	85.7				71.4			0
90.	R	95.9			98.6				93.2		6.8	1.4		Güdül Havuz (2022)
91.	R 2019–20	97.5							90			0	Sputum	Şenol et al. (2022)
		100							83.8			10.5	Deep tracheal aspirate
	R 2020–21	83.3							50			0	sputum
		100							93.8			9.2	Deep tracheal aspirate

R(Resistance),S( Ssusceptible), Amoxicillin/clavulanate (AMC), Ampicillin (AMP), Ampicillin/sulbactam ( AMS), Aztreonam (ATM), Amikacin (AMK), Cefepime (CFPM), Cefixime (CFM), Cefotaxime( CTX), Cefoperazone-sulbactam( CS), Ceftazidime (CAZ), Ceftriaxone (CRO), Ciprofloxacin (CIP), Doxycycline (DOX), Ertapenem (ETP), Gentamicin (GEN),Imipenem (IPM),Levofloxacin (LVX),Meropenem (MEM), Minocycline (MIN), Netilmicin (NET), Nitrofurantoin (NIT), Ofloxacin (OFL), Piperacillin (PIP), Piperacillin/tazobactam (TZP), Sulbactam (SUL), Tetracycline (TET),Tobramycin (TOB), Trimethoprim-Sulfamethoxazole (SXT), Ticarcillin (TIC), Ticarcillin/clavulanate (TCC), Tigecycline( TGC), Colistin (CST), Cefoperazone( CFP), Cephalothin (CEF), Cefuroxime( CXM), Polymyxin B (PB), Fosfomycin (FO), Rifampicin (RIF), Doripenem (DOR), Moxifloxacin (MOXI), Chloramphenicol

Back to article page